Lecanemab for Alzheimer Disease Safe, Feasible in Real-World Practice

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on May 15, 2025.

By Lori Solomon HealthDay Reporter

THURSDAY, May 15, 2025 -- Treatment of Alzheimer disease with lecanemab is feasible in a specialty memory clinic, and the frequency of significant adverse events is similar to clinical trials, according to a study published online May 12 in JAMA Neurology.

Madeline Paczynski, from the Washington University School of Medicine in St. Louis, and colleagues examined the feasibility and safety of treating patients in specialty memory clinics with lecanemab. Analysis included 234 patients with early symptomatic Alzheimer disease initiating lecanemab (Aug. 1, 2023, to Oct. 1, 2024).

The researchers found that infusion-related reactions occurred in 37 percent of patients and were typically mild. Of the 194 patients at risk for amyloid-related imaging abnormalities (ARIA), just under one-quarter (23 percent) had at least one microhemorrhage and/or superficial siderosis before initiation of lecanemab. Twenty-two percent of patients developed ARIA over an average treatment period of 6.5 months, including 15 percent who developed ARIA with edema/effusion with or without ARIA with hemorrhage/hemosiderin deposition, and 6.7 percent developed isolated ARIA with hemorrhage/hemosiderin deposition. Of those developing ARIA, 5.7 percent were symptomatic and two of 11 developed clinically severe symptoms. No patients developed a macrohemorrhage or died. Symptomatic ARIA was seen at a rate of 27 percent in patients with mild dementia and a rate of 1.8 percent for those with mild cognitive impairment or very mild dementia.

"Our study shows that WashU Medicine’s outpatient clinic has the infrastructure and expertise to safely administer and care for patients on lecanemab, including the few who may experience severe side effects, leading the way for more clinics to safely administer the drug to patients," Barbara Joy Snider, M.D., Ph.D., also from Washington University, said in a statement.

Several authors disclosed ties to the pharmaceutical and biotechnology industries.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-05-16 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords